Ovid Therapeutics Inc. Revenue
Ovid Therapeutics Inc. (OVID) reported Revenue of $733.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- Ovid Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $733.00K, a 88.31% decline year-over-year.
- Ovid Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Ovid Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $718.00K, a 844.74% increase year-over-year.
- Ovid Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $132.00K, a 23.70% decline year-over-year.
- Ovid Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $7.25M, a 1181.27% increase from fiscal 2024.
- Ovid Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $566.00K, a 44.39% increase from fiscal 2023.
- Ovid Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $392.00K, a 73.91% decline from fiscal 2022.
- Ovid Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.50M, a 99.28% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 105 month | Revenue from Contract with Customer, Excluding Assessed Tax 108 month | Revenue from Contract with Customer, Excluding Assessed Tax 111 month | Revenue from Contract with Customer, Excluding Assessed Tax 114 month | Revenue from Contract with Customer, Excluding Assessed Tax 117 month | Revenue from Contract with Customer, Excluding Assessed Tax 120 month | Revenue from Contract with Customer, Excluding Assessed Tax 123 month | Revenue from Contract with Customer, Excluding Assessed Tax 126 month | Revenue from Contract with Customer, Excluding Assessed Tax 132 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $733.00K 10-Q · filed 2026-08-13 | $733.00K 10-Q · filed 2026-08-13 | $1.45M derived: sum of 3 quarters · filed 2026-08-13 | $1.58M derived: sum of 4 quarters · filed 2026-08-13 | |||||||||||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $718.00K derived: sum of 2 quarters · filed 2026-05-12 | $850.00K derived: sum of 3 quarters · filed 2026-05-12 | $7.12M derived: sum of 4 quarters · filed 2026-08-13 | |||||||||||||
| 2025-12-31 | $718.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $850.00K derived: sum of 2 quarters · filed 2026-03-18 | $7.12M derived: sum of 3 quarters · filed 2026-08-13 | $7.25M 10-K · filed 2026-03-18 | |||||||||||||
| 2025-09-30 | $132.00K 10-Q · filed 2025-11-12 | $6.40M derived: sum of 2 quarters · filed 2026-08-13 | $6.53M 10-Q · filed 2025-11-12 | $6.61M derived: sum of 4 quarters · filed 2026-08-13 | |||||||||||||
| 2025-06-30 | $6.27M 10-Q · filed 2026-08-13 | $6.40M 10-Q · filed 2026-08-13 | $6.48M derived: sum of 3 quarters · filed 2026-08-13 | $6.65M derived: sum of 4 quarters · filed 2026-08-13 | |||||||||||||
| 2025-03-31 | $130.00K 10-Q · filed 2026-05-12 | $206.00K derived: sum of 2 quarters · filed 2026-05-12 | $379.00K derived: sum of 3 quarters · filed 2026-05-12 | $548.00K derived: sum of 4 quarters · filed 2026-05-12 | $223.60M 10-Q · filed 2025-05-13 | ||||||||||||
| 2024-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $249.00K derived: sum of 2 quarters · filed 2026-03-18 | $418.00K derived: sum of 3 quarters · filed 2026-03-18 | $566.00K 10-K · filed 2026-03-18 | |||||||||||||
| 2024-09-30 | $173.00K 10-Q · filed 2025-11-12 | $342.00K derived: sum of 2 quarters · filed 2025-11-12 | $490.00K 10-Q · filed 2025-11-12 | $632.00K derived: sum of 4 quarters · filed 2025-11-12 | $223.40M 10-Q · filed 2024-11-12 | ||||||||||||
| 2024-06-30 | $169.00K 10-Q · filed 2025-08-13 | $317.00K 10-Q · filed 2025-08-13 | $459.00K derived: sum of 3 quarters · filed 2025-08-13 | $568.00K derived: sum of 4 quarters · filed 2025-08-13 | $223.20M 10-Q · filed 2024-08-13 | ||||||||||||
| 2024-03-31 | $148.00K 10-Q · filed 2025-05-13 | $290.00K derived: sum of 2 quarters · filed 2025-05-13 | $399.00K derived: sum of 3 quarters · filed 2025-05-13 | $474.00K derived: sum of 4 quarters · filed 2025-05-13 | $223.00M 10-Q · filed 2024-05-14 | ||||||||||||
| 2023-12-31 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $251.00K derived: sum of 2 quarters · filed 2025-03-11 | $326.00K derived: sum of 3 quarters · filed 2025-03-11 | $392.00K 10-K · filed 2025-03-11 | $391.69K 10-K · filed 2024-03-08 | $222.80M 10-K · filed 2024-03-08 | |||||||||||
| 2023-09-30 | $109.00K 10-Q · filed 2024-11-12 | $108.97K 10-Q · filed 2023-11-03 | $184.00K derived: sum of 2 quarters · filed 2024-11-12 | $250.00K 10-Q · filed 2024-11-12 | $250.13K 10-Q · filed 2023-11-03 | $296.28K derived: sum of 4 quarters · filed 2024-11-12 | $222.80M 10-Q · filed 2023-11-03 | ||||||||||
| 2023-06-30 | $75.00K 10-Q · filed 2024-08-13 | $141.00K 10-Q · filed 2024-08-13 | $141.16K 10-Q · filed 2023-08-04 | $187.28K derived: sum of 3 quarters · filed 2024-08-13 | $198.38K derived: sum of 4 quarters · filed 2024-08-13 | $222.60M 10-Q · filed 2023-08-04 | |||||||||||
| 2023-03-31 | $66.00K 10-Q · filed 2024-05-14 | $66.16K 10-Q · filed 2023-05-05 | $112.28K derived: sum of 2 quarters · filed 2024-05-14 | $123.38K derived: sum of 3 quarters · filed 2024-05-14 | $123.38K derived: sum of 4 quarters · filed 2024-05-14 | $222.60M 10-Q · filed 2023-05-05 | |||||||||||
| 2022-12-31 | $46.28K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $57.38K derived: sum of 2 quarters · filed 2024-03-08 | $57.38K derived: sum of 3 quarters · filed 2024-03-08 | $1.50M 10-K · filed 2024-03-08 | $222.50M 10-K · filed 2023-03-13 | ||||||||||||
| 2022-09-30 | $11.10K 10-Q · filed 2023-11-03 | $11.10K derived: sum of 2 quarters · filed 2023-11-03 | $1.46M 10-Q · filed 2023-11-03 | ||||||||||||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-04 | $1.45M 10-Q · filed 2023-08-04 | |||||||||||||||
| 2022-03-31 | $1.45M 10-Q · filed 2023-05-05 | ||||||||||||||||
| 2021-12-31 | $208.38M 10-K · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |